| Outcome Measures: |
Primary: Trial feasibility metric: number of screened patients, 3 months|Trial feasibility metric: number of eligible patients, 3 months|Trial feasibility metric: number of patients approached for consent, 3 months|Trial feasibility metric: proportion of eligible patients not consenting, 3 months|Trial feasibility metric: reasons for non-consent, 3 months|Trial feasibility metric: characteristics of consenting subjects and non-consenting patients, To examine baseline demographics and clinical factors, such as: mean age, median age, proportion female sex, other demographics, proportion with type I diabetes, proportion with type II diabetes, hemoglobin A1c on admission, reasons for admission, 3 months|Trial feasibility metric: proportion of enrolled subjects completing the intervention, 3 months|Trial feasibility metric: proportion of enrolled subjects disenrolling, 3 months|Trial feasibility metric: reasons for disenrollment, 3 months | Secondary: Hyperglycemia, Frequency of blood glucose concentrations that are hyperglycemic (\> 180 mg/dL), During hospitalization (maximum length 7 days)|Patient satisfaction, Satisfaction with inpatient diabetes care, as measured by the Diabetes Treatment Satisfaction Questionnaire for Inpatients (DTSQ-IP) adapted for use in the United States, At the end of hospitalization (maximum length 7 days)|Hypoglycemia, Frequency of hypoglycemia (blood glucose concentration \< 70 mg/dL) and frequency of severe hypoglycemia (blood glucose concentration \< 40 mg/dL), During hospitalization (maximum length 7 days)
|
